A Confirmation Study of Eribulin in Combination With Capecitabine
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Metastatic Breast Cancer
Related studies linked through entity extraction aliases.
Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment
- Status
- COMPLETED
- Phase
- PHASE2
High Resolution 3D Diffusion-weighted Breast MRI
- Status
- TERMINATED
- Phase
- N/A
A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients
- Status
- UNKNOWN
- Phase
- PHASE1
Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women
- Status
- UNKNOWN
- Phase
- PHASE2
Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE2
Safety Study of Multiple-Vaccine to Treat Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A